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Abstract
Background and Aim: This meta-analysis aimed to estimate the incidence of splanchnic
vein thrombosis (SVT) in patients with acute pancreatitis and assess the effects of therapeu-
tic anticoagulation.
Methods: Systematic searches of the Medline, Embase, and Cochrane databases were
undertaken to identify studies reporting the incidence and outcomes associated with SVT
in patients with acute pancreatitis. The pooled incidence, odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated using a random effects model. PROSPERO
database registration no. CRD 42021230912.
Results: Only 18 of the 238 studies identified met the inclusion criteria. Of the 943 patients
who had SVT, 264 (28.0%) received anticoagulation. The pooled incidence of SVT at first
presentation of acute pancreatitis was 15% (95% CI 5 to 26%), but was 17% (95% CI 14 to
20%) in all studies. Recanalization was more likely to occur in the anticoagulation-treated
than in the untreated group (OR 0.51, 95% CI 0.31 to 0.83, P = 0.007). There were no dif-
ferences in hemorrhagic complications (OR 2.27, 95% CI 0.81 to 6.37, P = 0.12) or overall
mortality (OR 2.37, 95% CI 0.86 to 6.52, P = 0.10) in relation to the use of anticoagulation.
The overall incidence of portal hypertension in patients was 60% (95% CI 55 to 65%).
However, it was not possible to determine the incidence in each group.
Conclusions: The incidence of SVT in patients with acute pancreatitis is significant.
Treatment with anticoagulants improved the odds of recanalization but did not increase
the risk of hemorrhagic complications or overall mortality.
Introduction
Vascular complications associated with acute pancreatitis are
common and are a major cause of morbidity and mortality.
Splanchnic vein thrombosis (SVT) is a recognized venous compli-
cation of acute pancreatitis resulting from a combination of both
local and systemic prothrombotic factors that are not completely
understood. The term SVT encompasses the three sites of
portomesenteric thrombosis: splenic vein thrombosis (SpVT),
portal vein thrombosis (PVT), and superior mesenteric vein throm-
bosis (SMVT), with SpVT being the commonest in patients with
acute pancreatitis.1,2
More severe presentations of acute pancreatitis, necrotizing
acute pancreatitis and recurrent presentations have been shown
to have a higher occurrence of SVT.1,3 However, other studies
have suggested that SVT may occur on index presentations and
in more moderate cases of acute pancreatitis.4–6 SVT is often
asymptomatic and identified incidentally on imaging, although in
some instances it can present with symptoms associated with
life-threatening ischemia.7–9 If left untreated, SVT can lead to
complications such as portal hypertension, mesenteric ischemia
and infarction.10 The use of unfractionated heparin or low
molecular weight heparin followed by transition to an oral vitamin
K antagonist is the most common approach to attempt to recana-
lize the vein and avoid further complications following SVT.
There is, however, a paucity of studies assessing the efficacy and
risks of anticoagulation.11,12 It is possible that the sooner anticoag-
ulation is initiated, the more likely is successful recanalization to
occur.7,11 However, the decision to treat SVT actively must be bal-
anced with the risk of bleeding secondary to other vascular com-
plications associated with acute pancreatitis, such as a bleed into
a pseudocyst, erosion of branches of the coeliac axis and superior
mesenteric artery, and development of pseudoaneurysms.13,14
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Due to the heterogenous presentation of SVT, it is likely to be
underdiagnosed and, therefore, the exact incidence in the setting
of acute pancreatitis is not known.15 Moreover, there is also a pau-
city of high-quality evidence evaluating use of anticoagulation
regimens and the overall outcomes of patients who develop SVT
associated with acute pancreatitis. The aim of this systematic
review and meta-analysis was to determine the incidence and out-
comes of SVT in patients with acute pancreatitis managed with
and without anticoagulation.
Methods
The systematic review was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) statement.16 The protocol was registered with the
PROSPERO database (https://www.crd.york.ac.uk/prospero/
Registration No. CRD 42021230912).
Literature search. A comprehensive and systematic search
of the Medline, EMBASE, Cochrane Library and Clinicaltrials.
org databases from January 1947 to February 2021 was performed
to identify studies reporting the incidence and or outcomes of SVT
in acute pancreatitis.
The search terms included: [“acute pancreatitis”] AND [“portal
vein thrombosis” or “venous thromboembolism” or “venous
thrombosis” or “VTE” or “liver vein thrombosis”] AND
[“anticoagulation” or “thromboembolism treatment” or “heparin”
or “anticoagulant agent” or “enoxaparin” or “treatment dose
enoxaparin” or “low molecular weight heparin”] mapped to corre-
sponding Medline Subject Headings (MeSH). Hand searches of
thesis repositories, relevant conference abstracts and bibliogra-
phies of relevant studies were undertaken to ensure comprehensive
study inclusion. Previously conducted systematic reviews on this
subject were also identified during this process. No language or
geographical limitations were applied.
Article selection. The titles and abstracts of studies identi-
fied from the searches were screened for suitability, against the in-
clusion criteria independently by two study authors (F. S. A,
A. A.). The remaining full-text articles were screened in detail in-
dependently and all discordance adjudicated by a third reviewer
(S. S.).
Inclusion and exclusion criteria. Studies were included
if they were performed on adult human subjects with a primary di-
agnosis of acute pancreatitis and reported on SVT in all or some of
their cohort. They also had to report at least one relevant clinical
outcome. Abstracts were only included if they were not published
as full papers.
Studies in children, or those in adults but not reporting SVT, or
any relevant clinical outcome were excluded. Animal studies were
not considered, as were case reports, correspondence, comments
and editorials.
Outcomes. The primary outcome was the incidence of SVT in
patients with acute pancreatitis overall and then incidence of SVT
at first presentation of acute pancreatitis separately.
Secondary outcomes included recanalization in
anticoagulation-treated versus untreated patients, hemorrhagic
complications, incidence of portal hypertension and mortality.
Data extraction. Studies identified from the database search
were screened based on titles and abstracts and independently
assessed by two reviewers. Three reviewers then independently
assessed the full text of the retrieved studies to ensure they met
the inclusion criteria, with any dissenting opinions resolved by a
consensus decision. A standardized data collection form was used
to collate information on incidence and outcomes from the in-
cluded articles. Data on individual study characteristics included:
first author, publication year, country, number of patients with
acute pancreatitis, number of patients who developed SVT,
number treated with anticoagulation, type, dose and route of anti-
coagulant therapy, and underlying etiology of acute pancreatitis.
Demographic characteristics, such as age and sex in each study
were extracted if reported.
Statistical analysis. Meta-analyses of pooled data were per-
formed using Review Manager (RevMan) version 5.3.17 Statistical
analysis was performed using STATA version 15 (StataCorp,
College Station, TX, USA). For dichotomous outcomes, the odds
ratios (ORs) were calculated with their respective 95% confidence
intervals (95% CI) using the Mantel–Haenszel random-effects
model. To quantify the incidence of SVT as a proportion of total
number of patients, a meta-analysis of proportions based on the
number of SVT in acute pancreatitis as reported in each study
was undertaken. To achieve this, a Freeman–Tukey transformation
was used to establish a variance of the raw proportions of each
study and then pooled using a random effects model. The quantity
of heterogeneity was measured using the I2 statistic with I2 ≥ 75%
considered to represent high heterogeneity.
Risk of bias. The risk of bias of the included studies was
assessed using the Newcastle–Ottawa Scale18 for non-randomized
studies and studies were reported as having low, moderate, or high
risk of bias.
Publication bias. Publication bias was assessed by visual in-
spection of asymmetry in the funnel plot based on the outcome of
failure of recanalization.
Results
Description of the included studies. A total of 236
studies were identified from the combined electronic database
searches with an additional 19 references identified from hand
searches (Fig. 1). After critical review, 18 observational (15 retro-
spective and 3 prospective) studies published between 2008 and
2020 met the inclusion criteria.1,3,4,8,19–32 Seven of these studies
were published only in abstract form.21–25,31,32 The studies origi-
nated from North America (n = 9), Europe (n = 6), and Asia
(n = 3) (Table 1).
Nine studies specified the protocol for anticoagulation
(Table 1)3,21,22,24,25,28,30–32 and indications included triple vessel
involvement,8 SVT in the absence of varices or collaterals,4,31
Splanchnic vein thrombosis FS Anis et al.
2 Journal of Gastroenterology and Hepatology •• (2021) ••–••
© 2021 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
presence of pulmonary emboli,4,8,31 presence of deep vein
thrombosis,3,4,31 stroke during admission,3 and presence of
complications as a result of SVT.8 Inter-study and intra-study var-
iability was observed in relation to the therapeutic anticoagulation
regimens and duration of treatment (Table 1).
Patient characteristics. A total of 943 patients with acute
pancreatitis developed SVT across the 18 included studies. Four-
teen studies specified the age of patients with the median age of
patients who developed SVT being 53 years (interquartile range
50.6–56.3 years). There was a male preponderance (67.3%)
among patients who developed SVT in the nine studies that re-
ported the sex. Overall, 264 of the 943 (28.0%) patients diagnosed
with SVT received therapeutic anticoagulation (Table 2).
Incidence of splanchnic vein thrombosis in
patients with acute pancreatitis. A total of 16 studies
reported incidence rates of SVT in acute pancreatitis. Three studies
recruited only patients with a first presentation of acute
pancreatitis.3,8,22 The total number of patients with a first presenta-
tion of acute pancreatitis patients was 335, of whom 53 developed
SVT. The incidence quoted from the individual studies ranged
from 6% to 23%. The pooled incidence was 15% (95% CI 5% to
26%).
Another 13 studies reported on all presentations of acute pancre-
atitis without distinguishing between first or subsequent presenta-
tions, with 816 patients found to have SVT with incidence rates
ranging between 2% and 51%.1,4,20,21,23,24,26–32
The overall incidence of SVT across the 16 studies was 17%
(95% CI 14% to 20%). Significant heterogeneity was observed
among studies (I2 = 98.2%) despite stratification for incidence at
first presentation, and for all presentations of acute pancreatitis.
Distribution of splanchnic vein thrombosis. Four-
teen studies, including 741 patients reported on the extent and dis-
tribution of thrombosis across the splanchnic vessels. These results
are summarized in Table 3. Isolated SpVTwas the most commonly
identified form of SVT in 47.6% of patients, followed by isolated
PVT in 15.5%. Thrombotic involvement of all the three splanchnic
vessels was observed in only 7.6% of patients.
Etiology of acute pancreatitis associated with
splanchnic vein thrombosis. Seven studies reported the
etiology of acute pancreatitis in 328 patients. The most common
cause of pancreatitis in patients also identified to have SVT was
gallstones in 97 patients (29.6%), closely followed by alcohol
consumption in 92 patients (28.0%). Idiopathic causes and
hypertriglyceridemia were responsible in 68 (20.7%) and 16
patients (4.9%), respectively. The least common etiologies were
iatrogenic and drug-induced pancreatitis in 7 patients each
(2.1%). The remaining 48 patients (14.6%) were reported to have
developed acute pancreatitis due to “other” or unspecified reasons.
Secondary outcomes. Although no distinction was made
between the anticoagulated and control groups, four studies
Figure 1 PRISMA diagram.
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reported the overall presence of portal hypertension in the patients
who developed SVT, with a pooled incidence of 60% (95% CI
55% to 65% I2 = 0%). Outcomes of the patients in the treatment
and control groups are summarized in Figure 2. The results show
that recanalization of the thrombosed veins was more likely to oc-
cur in patients who received anticoagulation (Fig. 2a). There were
no statistically significant differences between the groups when
hemorrhagic complications (Fig. 2b), and overall mortality
(Fig. 2c) were considered. However, mortality rates in the
anticoagulated and untreated groups were 23.4% and 18.3%,
respectively. Subgroup analysis of full-text articles only (Fig. 3)
also demonstrated that recanalization was more likely to occur in
the anticoagulated group. The differences in hemorrhagic
complications and mortality between the two groups were also
not statistically significant.
Five studies reported both the overall mortality in the acute
pancreatitis cohort without SVT and the mortality in those that de-
veloped an SVT. We found no difference in the risk of mortality
between the two groups; 5% (95% CI 0% to 10%) in the former
group and 7% (95% CI 2% to 12%) in the latter.
Risk of bias and publication bias. The majority of stud-
ies (77.8% [14/18]) were rated as having a moderate risk of bias,
due to their retrospective nature, low number of patients and no
detailed description of how patients were allocated to receive
anticoagulation treatment or no treatment (Table 1). Other studies
(22.2% [4/18]) reported little or no information on cohort identifi-
cation and were noted to give anticoagulation to less than 10% of
their population. There was, however, no significant asymmetry in
the plot for publication bias (Fig. 4).
Discussion
This systematic review found a contemporary data set of studies
published between 2008 and 2020 to define the incidence of
SVT in patients with acute pancreatitis. The pooled incidence from
the three studies reporting SVT at first presentation of acute
pancreatitis was 15%, as compared with the overall pooled inci-
dence of SVT which was 17%, albeit with clinical and statistical
heterogeneity among studies. Treatment with anticoagulation led
to significant improvements in the rate of recanalization. There
was no statistically significant increase in hemorrhagic complica-
tions or overall mortality. However, mortality in the anticoagulated
group was 23.4% compared with 18.3% in the untreated group.
Absence of a statistically significant difference in mortality could
possibly be because of a type II error.
Table 1 Study characteristics




Anticoagulation regimen Risk of bias
Harris 200825 USA Retrospective — 63 Unspecified High
Pribramska 200932 USA Retrospective 1155 50 (4.3%) Unspecified Moderate
Vyas 200924 UK Retrospective 87 22 (25.3%) Unspecified High
Gonzelez 20111 UK Prospective 127 20 (15.7%) A) LMWH (1 mg/kg)B) Warfarin
(INR 1.8–2.0)(TD: Unspecified)
Moderate
Muddana 201231 USA Prospective 193 41 (21.2%) Unspecified Moderate
Hall 201319 UK Retrospective — 11 LMWH (not adjusted for weight) ±
WarfarinUH ± WarfarinWarfarin alone
(TD: 2 months  lifelong)
High
Harris 20134 USA Retrospective 2454 45 (1.8%) (A) MWH: 1 mg/kg BD,UH: Initial bolus
80 U/kg + initial infusion of 18 U/kg/h
Warfarin (INR 2–3) (TD: 3–12 months)
Moderate
Easler 20143 USA Retrospective 122 22 (18.0%) Unspecified Moderate
Toqué 201528 France Retrospective 318 19 (6.0%) (B) Unspecified Moderate
Yang 201523 USA Retrospective 967 21 (2.2%) (A) UH, direct thrombin inhibitor (B)
Warfarin (TD: unspecified)
Moderate
Anderson 201721 USA Retrospective 4980 128 (2.6%) Unspecified Moderate
Wang 201722 USA Retrospective 108 7 (6.5%) Unspecified High
Ahmed 201829 India Retrospective 96 26 (27.1%) — Moderate
Garret 201830 UK Retrospective 148 76 (51.4%) Unspecified Moderate
Junare 20208 India Prospective 105 24 (22.9%) (A) UH
(B) Warfarin (INR 2–3) (TD: unspecified)
Moderate
Maatman 202026 USA Retrospective 570 257 (45.1%) — Moderate
Pagliari 202020 Italy Retrospective 221 27 (12.2%) (A) LMWH 100UI/kg BD (B) Warfarin
(INR 2–3), Fondaparinux (7.5 g OD),
apixaban
(5 mg BD) (TD: 1.5–9 months)
Moderate
Zhou 202027 China Retrospective 273 84 (30.8) LMWH TD: BD Moderate
(A) Initial management, (B) subsequent management/management on discharge.
INR, international normalized ratio; LMWH, low molecular weight heparin; TD, treatment duration; UH, unfractionated heparin.
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The overall incidence of SVT in patients with acute pancreatitis
in the literature is probably underestimated, as most cases reported
on cross sectional imaging are found incidentally,15 and the ab-
sence of imaging in mild to moderate cases of pancreatitis could
lead to co-existing SVT being missed.5 A previous systematic re-
view reported a pooled incidence of SVT in acute pancreatitis of
16.6% (95% CI 10.0% to 24.5%, I2 = 98%, P < 0.001), ranging
between 0.3% and 62.1%,33 similar to our study. Further
epidemiological studies would be necessary to define the true inci-
dence within different populations. Our study has also confirmed
that SpVT is the most common subtype of SVT observed in pa-
tients with acute pancreatitis.1–4,8,9
The rate of spontaneous recanalization in patients with SVT is
reported to be approximately 30%, suggesting that not all patients
require therapeutic anticoagulation to aid recovery. It has been
suggested that treatment should be reserved for those who develop
Table 2 Patient demographics








No. of patients in control
group
No. of patients who received
anticoagulation
Harris 200825 63 56 — — 38 25
Pribramska
200932
50 — 34 16 42 8
Vyas 200924 22 — — — 20 2
Gonzelez
20111
20 53.5 9 11 16 4
Muddana
201231
41 51.5 — — 34 7
Hall 201319 11 58 6 5 4 7
Harris 20134 45 58 31 14 28 17
Easler 20143 22 54 14 8 16 6
Toqué 201528 19 57 17 2 4 15
Yang 201523 21 52.4 — — 9 12
Anderson
201721
128 51.4 73 55 71 57
Wang 201722 7 48 — — 6 1
Ahmed 20182926 — — — — —
Garret 201830 76 — — — 37 39
Junare 20208 24 36.6 19 5 12 12
Maatman
202026
257 52 — — — —
Pagliari 20202027 55.1 23 4 11 16
Zhou 202027 84 42.5 — — 48 36
Table 3 Distribution of splanchnic vein thrombosis
Reference Site of thrombus
PVT SpVT SMVT PVT + SpVT SMVT + SpVT PVT + SMVT PVT + SpVT + SMVT Unspecified
Pribramska 200932 3 29 4 4 0 2 4 4
Gonzelez 20111 5 8 1 4 1 0 1 0
Hall 201319 4 0 0 3 1 1 2 0
Harris 20134 7 17 4 4 4 4 5 0
Easler 20143 1 13 1 2 0 1 4 0
Toqué 201528 6 7 0 0 4 0 2 0
Yang 201523 3 7 3 2 3 2 1 0
Anderson 201721 48 57 0 23 0 0 0 0
Wang 201722 4 2 1 0 0 0 0 0
Ahmed 201829 4 15 0 3 0 0 4 0
Junare 20208 0 11 0 4 0 0 9 0
Maatman 202026 23 128 18 21 36 13 18 0
Pagliari 202020 1 9 0 2 10 1 4 0
Zhou 202027 6 50 16 4 4 2 2 0
Total 115 (15.5%) 353 (47.6%) 48 (6.5%) 76 (10.3%) 63 (8.5%) 26 (3.5%) 56 (7.6%) 4 (0.5%)
PVT, portal vein thrombosis; SMVT, superior mesenteric vein thrombosis; SpVT, splenic vein thrombosis.
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complications.1 In our meta-analysis of all studies, 26.8% of
patients showed spontaneous recanalization without treatment,
while recanalization occurred in 50.4% of patients with SVT
who received anticoagulation treatment. The impact of the severity
of acute pancreatitis on the likelihood of spontaneous recanaliza-
tion could not be inferred from the individual studies.
Overall, in the present meta-analysis, the use of therapeutic
anticoagulation resulted in a statistically significant increase in rate
of recanalization (P = 0.007) but there was no increase in
hemorrhagic complications (P = 0.12) or mortality (P = 0.10). This
contrasts significantly with an earlier meta-analysis that included
only 5 studies, that suggested that there was no difference in either
recanalization rates (OR 1.02, 95% CI 0.59 to 1.77), or mortality
(OR 2.30, 95% CI 0.87 to 6.08) between treated and untreated
groups.34 The difference in outcomes between the two
meta-analyses can be accounted for by the larger number of pa-
tients with SVT included in our analysis.
The overall prognosis, in terms of portal hypertension, ischemia
and infarction, is similar in patients with incidental SVT or
symptomatic SVT.35 Given that therapeutic anticoagulation results
in an increased rate of splanchnic vein recanalization in acute
pancreatitis it would suggest that therapeutic anticoagulation
would be of use in both incidental and symptomatic SVT
groups.35–37 Patients with PVT and SMVT subtypes may have a
reduced rate of spontaneous recanalization and a higher mortality
rate; potentially implying that this specific cohort of patients with
SVT could benefit more from therapeutic anticoagulation.1 How-
ever, we did not observe a difference in overall mortality between
the treated and control groups to justify anticoagulation therapy.
It is difficult to distinguish between mortality related to progres-
sion of acute pancreatitis and due to complications from SVT asso-
ciated with pancreatitis alone. Our analysis of mortality risk in
patients with pancreatitis with and without SVT, found no differ-
ence in risk (pancreatitis without SVT group mortality of 5%
[95% CI 1% to 10%] and pancreatitis with SVT mortality of 7%
[95% CI 2% to 12%]). If the mortality risk was related to severe
acute pancreatitis alone and not the complications of SVT, then
it could possibly explain the lack of difference seen in mortality,
in spite of higher rates of recanalization in the treated group.
Furthermore, the lack of long-term follow-up in the included
studies makes it difficult to assess the long-term clinical impact
of recanalization on morbidity and SVT-specific mortality beyond
Figure 2 Forest plots comparing (a) recanalization rates, (b) hemorrhagic complications and (c) mortality in patients with splanchnic vein thrombosis
who received and did not receive anticoagulation—full-text studies and abstracts. [Color figure can be viewed at wileyonlinelibrary.com]
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the initial in-hospital stay. Further prospective studies are required
to assess the impact of anticoagulation on patients with SVT with
regard to the development of portal hypertension in the long term.
There are some limitations of this review. The studies included
were assessed have a moderate risk of bias, due to the risk of a
selection bias, lack of randomization or standardized treatment
protocols. Studies reporting on the same patient population were
excluded, however, in some instances we were unable to discern
whether the same group of authors utilized the same patient data
across two different studies, and therefore, the studies were
included.4,23,25,32 It was not possible to reach a conclusion as to
the anticoagulant of choice or the duration of treatment due to
the variability observed in these variables, between, and
within studies. Seven studies were published in abstract form
only and it was not possible to get the complete data set from
these.21–25,31,32
Figure 3 Forest plots comparing (a) recanalization rates, (b) hemorrhagic complications and (c) mortality in patients with splanchnic vein thrombosis
who received and did not receive anticoagulation—full-text studies only. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 4 Funnel plot demonstrating lack of publication bias based on
the outcome of failure of recanalization. [Color figure can be viewed at
wileyonlinelibrary.com]
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Not all studies stratified the severity of pancreatitis, thereby
preventing a comparison between the severity of pancreatitis and
the incidence of SVT. We were limited in our ability to compare
the risk of hemorrhagic complications and mortality in the studies
reporting recanalization rates due to the variability in reporting
these outcomes among them. While some studies suggest that
different subtypes of SVT may vary prognostically, we are unable
to compare them fully and recognize the need for further studies to
directly compare the outcomes associated with the different sub-
types. In addition, there were insufficient data to assess longer
term outcomes following anticoagulation.32
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